Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682518 | 0.88 | MMP2 (0.43) | ALDH1A1LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6676569 | 0.86 | CA2 (0.38) | LMNAL3MBTL1KDM4ETAAR1 | |
| SCHEMBL6679407 | 0.86 | SLC6A2 (0.43) | ALDH1A1HPGDLMNATP53HTT | |
| SCHEMBL6804926 | 0.84 | CA2 (0.36) | LMNAL3MBTL1KDM4ETAAR1 | |
| SCHEMBL6680578 | 0.83 | HPGD (0.42) | ALDH1A1HPGDLMNATP53SMN1; SMN2 | |
| SCHEMBL6677304 | 0.83 | CNR1 (0.54) | CNR1ALDH1A1HPGDLMNATP53 | |
| SCHEMBL6675932 | 0.82 | GAA (0.40) | ALDH1A1LMNASMN1; SMN2CHRNA7 | |
| SCHEMBL6677650 | 0.81 | CA2 (0.41) | LMNAL3MBTL1KDM4ETAAR1 | |
| SCHEMBL6677206 | 0.80 | F2 (0.40) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL6676723 | 0.80 | CA2 (0.43) | SLC6A4CNR1ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | SLC6A4 2109/4885CNR1 112/4885ALDH1A1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.